ストックスクリーナーアプリを入手
15.73
2.36%
-0.38
アフターアワーズ：
15.73
Nurix Therapeutics Inc (NRIX) 最新ニュース
NRIX: Degrader therapies advance in immunology, with key milestones expected for STAT6 and BTK programs - TradingView
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
VIX Spike: Can Nurix Therapeutics Inc sustain its profitabilityGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share ShelfWhat's Changed - Yahoo Finance
Stifel raised Nurix Therapeutics, Inc. (NRIX) price target to $35 and maintains buy ahead of 2026 catalysts - MSN
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
Is Nurix Therapeutics Inc forming a bullish divergenceWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Finviz
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Finviz
Research Analysts Offer Predictions for NRIX Q1 Earnings - MarketBeat
Published on: 2026-02-01 10:49:34 - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - 富途牛牛
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unpacking A 70% Upside Potential - DirectorsTalk Interviews
Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure - The Globe and Mail
Nurix Therapeutics chief legal officer Ring sells $73k in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics chief legal officer Ring sells $73k in stock - Investing.com UK
Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,895 Shares - MarketBeat
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Finviz
Nurix Therapeutics CSO Gwenn Hansen sells $81k in shares By Investing.com - Investing.com Canada
Nurix Therapeutics CFO Hans van Houte sells $61k in shares - Investing.com Canada
Big Picture: Can Artius II Acquisition Inc Equity Right be the next market leaderWeekly Stock Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Should I buy Nurix Therapeutics Inc stock now2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress - Sahm
Stock Analysis: Will Nurix Therapeutics Inc be affected by tariffsQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Momentum Shift: Can THTX expand into new marketsMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
HC Wainwright Raises Price Target for NRIX, Reaffirms Buy Rating - GuruFocus
Nurix Therapeutics price target raised to $35 from $33 at Stifel - TipRanks
Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) t - GuruFocus
Royal Bank Of Canada Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
NRIX: RBC Capital Raises Price Target and Maintains Outperform R - GuruFocus
NRIX: Stifel Raises Price Target to $35, Maintains 'Buy' Rating - GuruFocus
NRIX: Wells Fargo Lowers Price Target to $29, Maintains Overweig - GuruFocus
NRIX Analyst Jeet Mukherjee Reiterates Buy Rating, Target Stays at $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Earns "Buy" Rating from BTIG Research - MarketBeat
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo - TipRanks
Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler - TipRanks
NRIX: Needham Reiterates Buy Rating with Stable Price Target | N - GuruFocus
What 11 Analyst Ratings Have To Say About Nurix Therapeutics - Benzinga
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
A Look At Nurix Therapeutics (NRIX) Valuation As DAYBreak Phase 2 Trial Progresses - Sahm
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Nurix (NRIX) Achieves Key Milestone with Q4 Revenue and Program Launch - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 6.7%Time to Sell? - MarketBeat
Nurix Therapeutics Announces Initiation of DAYBreak™ Program for Bexobrutideg in Relapsed/Refractory CLL with Promising Phase 1 Results - Quiver Quantitative
Nurix Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q4 Revenue $13.6M, vs. FactSet Est of $13.4M - marketscreener.com
NRIX: Advanced pivotal CLL trials, grew revenue, and maintained strong cash reserves - TradingView
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):